Severe Hypertriglyceridemia Market Poised for Transformational Growth Amid Breakthrough Therapies and Rising Unmet Needs

DelveInsight’s latest analysis highlights a rapidly evolving landscape in the Severe Hypertriglyceridemia (SHTG) Market, driven by rising disease prevalence, growing awareness of cardiovascular risks, and the emergence of novel, mechanism-driven therapies. Despite the availability of conventional lipid-lowering treatments, Severe Hypertriglyceridemia continues to impose a significant clinical and economic burden worldwide, underscoring a critical unmet need for more effective and durable treatment options.

According to DelveInsight’s report, “Severe Hypertriglyceridemia Treatment Market Insights, Epidemiology and Market Forecast – 2034,” the total Severe Hypertriglyceridemia Market Size in the 7MM (United States, EU4, the United Kingdom, and Japan) was approximately USD 1.4 billion in 2023 and is projected to grow substantially through 2034. This growth is expected to be fueled by the anticipated approval and adoption of innovative therapies targeting the underlying biology of triglyceride metabolism.

Severe Hypertriglyceridemia: A High-Burden, Underaddressed Metabolic Disorder

Severe Hypertriglyceridemia is characterized by extremely elevated triglyceride levels—often more than three times the normal range, typically exceeding 500 mg/dL. Patients with SHTG face a heightened risk of serious complications, including cardiovascular disease (CVD) and acute pancreatitis, a potentially life-threatening condition. While SHTG often remains asymptomatic, individuals with triglyceride levels above 2,000 mg/dL may experience recurrent abdominal pain, nausea, vomiting, xanthomas, and repeated episodes of pancreatitis.

The disease can arise from primary (genetic) causes, such as lipoprotein lipase (LPL) deficiency or apolipoprotein C-II deficiency, or from secondary causes linked to obesity, diabetes, alcohol consumption, and other metabolic disorders. Despite its severity, a significant proportion of patients remain undiagnosed or inadequately treated, representing a major gap in disease management.

Epidemiology Insights: Growing Patient Pool Across Major Markets

DelveInsight’s epidemiological analysis reveals that the total number of diagnosed prevalent SHTG cases across the 7MM reached nearly 3.6 million in 2023, with the United States accounting for the largest share at approximately 2.7 million cases. Among EU4 and the UK, Germany reported the highest number of cases, while Spain accounted for the lowest.

Alarmingly, the report estimates that nearly half of diagnosed patients do not receive treatment, highlighting systemic gaps in both diagnosis and therapeutic intervention. Secondary SHTG cases outnumber primary cases, reflecting the growing influence of lifestyle-related metabolic risk factors such as obesity, sedentary behavior, and diabetes.

Current Treatment Landscape: Incremental Benefits, Persistent Limitations

The current Severe Hypertriglyceridemia Treatment Market is dominated by traditional lipid-lowering agents, including statins, fibrates, niacin, and omega-3 fatty acids. Among these, statins lead the market, followed by fibrates and omega-3 fatty acids. While these therapies can modestly reduce triglyceride levels, they often fall short of achieving clinically meaningful reductions, particularly in patients with severe or genetically driven disease.

VASCEPA (icosapent ethyl), developed by Amarin Corporation, remains the only FDA-approved therapy specifically indicated for SHTG and cardiovascular risk reduction. Approved in the US in 2012 and in the EU in 2021 under the brand name VAZKEPA, VASCEPA has demonstrated benefits in triglyceride lowering and cardiovascular outcomes. However, its triglyceride-lowering effect is modest, and its use is associated with risks such as atrial fibrillation and bleeding.

As a result, despite the availability of these therapies, SHTG continues to significantly impact patients’ quality of life, reinforcing the urgent need for more effective, targeted treatments.

Emerging Therapies: A Paradigm Shift in SHTG Management

The SHTG pipeline is undergoing a significant transformation, with novel therapies targeting apolipoprotein C-III (ApoC-III) and other key metabolic pathways. Leading Severe Hypertriglyceridemia Companies include Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, 89bio, NorthSea Therapeutics B.V., and MediciNova, among others.

Olezarsen: A First-in-Class Opportunity

Olezarsen, developed by Ionis Pharmaceuticals, is a ligand-conjugated antisense oligonucleotide (ASO) targeting ApoC-III. Currently in Phase III development for SHTG, olezarsen has demonstrated robust triglyceride reductions not achievable with existing therapies. With a potential US approval anticipated between 2026 and 2027, olezarsen is expected to gain a first-mover advantage and is widely viewed as a future blockbuster in the SHTG market.

Plozasiran: The Only siRNA Contender

Plozasiran (ARO-APOC3), developed by Arrowhead Pharmaceuticals, is the only small interfering RNA (siRNA) therapy in development for SHTG. By reducing ApoC-III production via RNA interference, plozasiran offers a differentiated and highly targeted approach. The therapy is currently in Phase III trials, with commercialization expected around 2027. As it nears market entry, plozasiran is poised to compete directly with olezarsen, potentially reshaping prescribing patterns away from statins toward triglyceride-specific therapies.

Other Notable Pipeline Assets

Additional emerging therapies include Pegozafermin (89bio), a recombinant protein designed to prolong FGF21 activity, and SEFA-1024 (NorthSea Therapeutics B.V.), a small molecule in Phase II development. Together, these agents reflect a diversified pipeline encompassing antisense oligonucleotides, siRNAs, recombinant proteins, and small molecules, all aimed at addressing longstanding unmet needs in SHTG.

Market Outlook: Strong Growth Through 2034

DelveInsight projects sustained growth in the Severe Hypertriglyceridemia Market through 2034, driven by multiple factors:

• Rising prevalence of hypertriglyceridemia linked to obesity, diabetes, and sedentary lifestyles

• Improved diagnostic tools and lipid profiling, enabling earlier identification of high-risk patients

• Increased awareness of cardiovascular and pancreatitis risks, prompting proactive disease management

• Supportive regulatory environments, accelerating the approval of innovative lipid-lowering therapies

• A strong R&D pipeline, attracting investment and driving adoption of next-generation treatments

Among the 7MM, the United States consistently represents the largest market, with an estimated USD 1.3 billion in 2023, while Germany leads among EU4 and the UK. By 2034, plozasiran is expected to capture the highest market share among emerging therapies, followed closely by olezarsen.

Expert Perspectives Reinforce Market Potential

Insights from Key Opinion Leaders (KOLs) emphasize the transformative potential of emerging therapies. Experts note that olezarsen has achieved triglyceride reductions “not currently possible with approved medications,” while also highlighting the need for long-term outcomes data to confirm reductions in heart attack and stroke risk. KOLs further acknowledge the continued role of statins in SHTG management but agree that novel ApoC-III–targeted therapies could redefine the standard of care.

About the Report

DelveInsight’s “Severe Hypertriglyceridemia Treatment Market Insights, Epidemiology and Market Forecast – 2034” delivers a comprehensive assessment of the SHTG landscape, including:

• Historical and forecasted epidemiology across the 7MM

• Current treatment practices and emerging therapies

• Market size, share, and growth opportunities through 2034

• Pipeline analysis, KOL insights, and qualitative intelligence (SWOT and conjoint analysis)

• Access, reimbursement, and pricing dynamics across key geographies

To explore detailed insights, competitive intelligence, and future opportunities in this rapidly evolving space, request access to the sample page of the “Severe Hypertriglyceridemia Treatment Market” report today.